on MIRA Pharmaceuticals (NASDAQ:MIRA)
MIRA Pharmaceuticals Reveals New Data on Ketamir-2 at Annual Pain Therapeutics Summit
MIRA Pharmaceuticals announced that new preclinical data on Ketamir-2 will be presented at the 18th Annual Pain Therapeutics Summit in Boston, MA on October 28-29, 2024. The data shows Ketamir-2 achieving a complete reversal of neuropathic pain in preclinical models.
The Summit is a notable forum for experts to discuss pain management innovations. MIRA's participation reveals its commitment to addressing unmet needs in neuropathic pain, a condition with limited treatments available.
Preclinical studies demonstrated Ketamir-2, an oral ketamine analog, to be effective in fully reversing neuropathic pain responses. These results point to Ketamir-2's promising potential as an innovative therapy with fewer side effects.
Dr. Itzchak Angel of MIRA, who will present the data, emphasized the groundbreaking nature of these findings, suggesting significant improvements over existing treatments.
MIRA is preparing to submit an IND application to the FDA by December 2024, with plans for human trials in 2025.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MIRA Pharmaceuticals news